SFX by Ex Libris Inc.

Title:	Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting
Source:	Physics in Medicine and Biology [0031-9155] Flynn, Ryan yr:2009

Basic

Full text

Full text available via EZB-NALIM-00482 IOP Archive NL

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Berwouts, D. "Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial." Radiotherapy and oncology 107.3 (2013): 310-6.
description	2.	Bowen, S. "On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function." Physics in medicine & biology 54.6 (2009): 1483-1501.
description	3.	Bentzen, Søren M M. "Theragnostic imaging for radiation oncology: dose-painting by numbers." The lancet oncology 6.2 (2005): 112-117.
description	4.	Bentzen, Sren M. "Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription." Seminars in radiation oncology 21.2 (2011): 101-110.
description	5.	Harada, H.. "Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy." The British journal of cancer 100.5 (2009): 747-757.
description	6.	GROSU, A. "Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer." International journal of radiation oncology, biology, physics 69.2 (2007): 541-551.
description	7.	Alber, M. "Hypoxia Dose Painting by Numbers: A Planning Study." International journal of radiation oncology, biology, physics 68.1 (2007): 291-300.
description	8.	Heukelom, J. "Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer." BMC cancer 13.1 (2013): 84-84.
description	9.	Schwartz, David L. "Adaptive radiotherapy for head and neck cancer-Dosimetric results from a prospective clinical trial." Radiotherapy and oncology 106.1 (2013): 80-84.
description	10.	De Neve, W. "Rational use of intensity-modulated radiation therapy: the importance of clinical outcome." Seminars in radiation oncology 22.1 (2012): 40-49.
description	11.	Soon, Q. "Diacetylbis(N(4)-methylthiosemicarbazonato) Copper(II) (CuII(atsm)) Protects against Peroxynitrite-induced Nitrosative Damage and Prolongs Survival in Amyotrophic Lateral Sclerosis Mouse Model." Journal of biological chemistry 286.51 (2011): 44035-44044.
description	12.	Meijer, G. "Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: Practical implications of using a broad or sharp brush." Radiotherapy and oncology 100.3 (2011): 396-401.
description	13.	Das, S. "A role for biological optimization within the current treatment planning paradigm." Medical physics 36.10 (2009): 4672-4682.
description	14.	Pene, F. "Toward theragnostics." Critical care medicine 37.1 Suppl (2009): 50-8.
description	15.	Parker, C. "Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer." International journal of radiation oncology, biology, physics 58.3 (2004): 750-7.
description	16.	Service, Robert F. "Nanotechnology Takes Aim at Cancer." Science 310.5751 (2005): 1132-1134.
description	17.	Misra, R. "Cancer nanotechnology: application of nanotechnology in cancer therapy." Drug discovery today 15.19-20 (2010): 842-850.
description	18.	Alber, M. "Implementation of hypoxia imaging into treatment planning and delivery." Radiotherapy and oncology 97.2 (2010): 172-175.
description	19.	Dong, X. "Age at diagnosis and prognosis among prostate cancer patients treated with radiotherapy: evidenced from three independent cohort studies." Annals of oncology (2018): 2019-2020.
description	20.	Beppu, T. "High-uptake areas on positron emission tomography with the hypoxic radiotracer 18F-FRP170 in glioblastomas include regions retaining proliferative activity under hypoxia." Annals of nuclear medicine 29.4 (2015): 336-341.